Professor25/iStock via Getty Images
DBV Technologies (NASDAQ:DBVT) reported positive two-year data from an ongoing Phase 3 study extension for its peanut allergy treatment Viaskin Peanut in toddlers aged one to three years old.
The company said that after 24 months of therapy, 56% of participants were able to consume a cumulative dose of 12 to 14 peanut kernels without meeting the predefined stopping criteria, with 81.3% able to reach an eliciting dose of three to four peanut kernels.
It noted that prior to treatment, the toddlers’ eliciting dose ranged from a fraction of a kernel to roughly one kernel. No treatment-related anaphylactic or treatment-related serious adverse events were reported during the second year of treatment.
“This is a promising outcome for a community of peanut allergic toddlers where accidental exposure poses significant risk,” said DBV Technologies CEO Daniel Tasse in a statement.
The company plans to highlight the data during a presentation at the American College of Allergy, Asthma and Immunology annual meeting on Nov. 11.